Accuracy of 99mTc-sestamibi scintimammography for breast cancer diagnosis

Moriguchi,Sonia M.; De Luca,Laurival A.; Griva,Beatriz L.; Koga,Kátia H.; Da Silva,Eduardo T.; De Luca Vespoli,Heloisa; Uemura,Gilberto

doi:10.3892/etm_00000033

Accuracy of 99mTc-sestamibi scintimammography for breast cancer diagnosis

Authors:
- Sonia M. Moriguchi
- Laurival A. De Luca
- Beatriz L. Griva
- Kátia H. Koga
- Eduardo T. Da Silva
- Heloisa De Luca Vespoli
- Gilberto Uemura
View Affiliations

Affiliations: Department of Nuclear Medicine, Barretos Cancer Hospital, São Paulo, Brazil. soniamoriguchi@terra.com.br
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000033
Pages: 205-209

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Scintimammography using 99mTc-sestamibi is a noninvasive and painless diagnostic imaging method that is used to detect breast cancer when mammography is inconclusive. Because of the advantages of labeling with 99mTc-sestamibi and its high efficiency in detecting carcinomas, it is the most widespread agent for this purpose. Its accumulation in the tumor has multifactorial causes and does not depend on the presence of architectural distortion or local or diffuse density variation in the breast. The objective of this study was to evaluate the accuracy of scintimammography for detecting breast cancer. One hundred and fifty-seven patients presenting 158 palpable and non-palpable breast nodules were evaluated. Three patients were male and 154 were female, aged between 14 and 81 years. All patients underwent scintimammography, and the nodule was subjected to cytological or histological study, i.e., the gold standard for diagnosing cancer. One hundred and eleven malignant and 47 benign nodules were detected, with predominance of ductal carcinomas (n=94) and fibroadenoma/fibrocystic condition (n=11/n=11), respectively. The mean size was 3.11 cm (7-10 cm) among the malignant nodules and 2.07 cm among the benign nodules (0.5-10 cm). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 89, 89, 95, 78 and 89%, respectively. Analysis on the histological types showed that the technique was more effective on tumors that were more aggressive, such as ductal carcinoma. In this study, 99mTc-sestamibi scintimammography was shown to be an important tool for diagnosing breast cancer when mammography was inconclusive.

View Figures

View References

1.	Sickles EA: Breast masses: mammographic evaluation. Radiology. 173:297–303. 1989. View Article : Google Scholar : PubMed/NCBI
2.	Donegan WL: Evaluation of a palpable breast mass. N Engl J Med. 327:937–942. 1992. View Article : Google Scholar : PubMed/NCBI
3.	Kopans DB: Rastreamento do câncer de mama. Kopans DB and Bertud M: Imagem da Mama. 2nd edition. Medsi; Rio de Janeiro: pp. 55–99. 2000
4.	Sickles EA: Mammographic features of 300 consecutive nonpalpable breast cancers. Am J Roentgenol. 146:661–663. 1986. View Article : Google Scholar : PubMed/NCBI
5.	Khalkhali I, Mena I and Diggles L: Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m setamibi. Eur J Nucl Med. 21:357–362. 1994. View Article : Google Scholar : PubMed/NCBI
6.	Kalisher L: Factors influencing false negative rates in xeromammography. Radiology. 133:297–301. 1979. View Article : Google Scholar : PubMed/NCBI
7.	Rosenberg RD, Hunt WC, Williamson MR, et al: Effects of age, breast density, ethnicity and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screnning mammograms in Albuquerque, New Mexico. Radiology. 209:511–518. 1998. View Article : Google Scholar
8.	Mandelson MT, Oestreicher N, Porter PL, et al: Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 92:1081–1087. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Mann BD, Giuliano AE, Basset LW, Barber MS, Hallauer W and Morton DL: Delayed diagnosis of breast cancer as a result of normal mammograms. Arch Surg. 118:23–24. 1983. View Article : Google Scholar : PubMed/NCBI
10.	Vespoli HM, De Luca LA, Rodrigues JR and Uemura G: Natureza histopatológica de microcalcificações presentes em lesões não nodulares classificadas como Birads 4. Rev Bras Mastol. (In press).
11.	Waxman AD, Ramanna L, Memsic LD, et al: Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med. 34:18–23. 1993.PubMed/NCBI
12.	Lyra M and Vamvakas I: Dosimetry in scintimammography by (99m)Tc-MuIotaBetaIota, (99m)Tc-tetrofosmin, (99m)Tc-(V) DMSA and 201TlCl compared with X-rays mammography. Hell J Nucl Med. 12:184–188. 2009.PubMed/NCBI
13.	Taillefer R: The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 19:16–40. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Chiu ML, Kronauge JF and Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med. 31:1646–1653. 1990.PubMed/NCBI
15.	Pwnica-Worms D, Kronauge JF and Ciu ML: Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 82:1826–1838. 1990. View Article : Google Scholar
16.	Carvalho PA, Chiu ML, Kronauge JF, et al: Subcellular distribuition and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med. 33:516–522. 1992.PubMed/NCBI
17.	Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I and Abdel-Dayem HM: Role of thallium 201 cloride and Tc99m methoxy-isobutyl-isonitrile sestamibi in evaluation of breast masses: correlation with immunohistochemical characteristic parameters Ki-63 PCNA, BCI-2 and angiogenesis in malignant lesions. Anticancer Res. 17:1639–1644. 1997.
18.	Cutrone JA, Yospur LS, Khalkhali I, et al: Immunohistologic assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions. J Nucl Med. 39:449–453. 1998.PubMed/NCBI
19.	Tierney S, Fenlon HM, Phelan N, O'Sullivan P, Ennis JT and Gorey TF: Scintimammography in the assessment of local recurrence following conservative breast surgery. Br J Surg. 85:511998.
20.	Cutrone JA, Khalkhali I, Yospur LS, et al: Tc-99m sestamibi scintimammography for the evaluation of breast masses in patients with radiographically dense breasts. Breast. 5:383–388. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Zegel H, Heller L, Edell S, Squires F and Rubin J: Tc-99m sestamibi scintimammography dense breast. Clin Nucl Med. 24:968–975. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Kuhn JC, Siegel A, Poplack S and Arrick B: Chest wall recurrence of breast cancer detected by scintimammography. Clin Nucl Med. 25:104–107. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Kolasinska AD, Cwikla JB, Buscombe JR, et al: Scintimammography in recurrent breast cancer: a primary or secondary role? Nucl Med Commun. 21:389–390. 2000. View Article : Google Scholar
24.	Usmani S, Khan HA, Niaz K, et al: Tc-99m-methoxy isobutyl isonitrile scintimammography: imaging postexcision biopsy for residual and multifocal tumor. Nucl Med Commun. 29:826–829. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Diggles L, Mena I and Khalkhali I: Technical aspects of prone dependent-breast scintimammography. J Nucl Med Technol. 22:165–170. 1994.
26.	Khalkhali I, Mena I and Jouanne E: Prone scintimammography in patients with suspicion of breast cancer. J Am Coll Surg. 78:491–497. 1994.
27.	Zajicek J: Aspiration biopsy cytology Part I Cytology of supra diaphragmatic organs. Basel: S. Karger; 4. pp. 37pp. 38pp. 481974
28.	Faraj M, Antunes LC and Ribeiro RM: Aspectos básicos da interpretação dos exames complementares. J Bras Med. 62:124–129. 1992.
29.	Siegel S: Estatística não Paramétrica (Para as Ciências do Comportamento). McGraw Hill. São Paulo: 1975.
30.	Fleiss JL: Statistical Methods for Rates and Proportions. John Wiley. New York: 1973.
31.	Rosner B: Fundamental of Biostatistics (2nd edition). Duxbury Press. Boston: 1986.
32.	Curi PR: Metodologia e Análise de Pesquisa em Ciências Biológicas. 2nd edition. Tipomic; Botucatu: 1998
33.	Harris JR, Hellman S, Henderson IC and Kinne DW: Breast Diseases. Lippincott. Philadelphia: 1987.
34.	Inanir S, Kiliç AK, Özdemir E and Zorlutuna Y: Technetium-99m-methylene diphosphonate scintimammography in male breast cancer. J Nucl Med. 39:28–29. 1998.PubMed/NCBI
35.	Liu M, Husain SS, Hameer HR and Gona JM: Detection of male breast cancer with Tc-99m methoxyisobutylisonitrile. Clin Nucl Med. 24:882–883. 1999. View Article : Google Scholar : PubMed/NCBI
36.	Marwah A, Kumar R, Bharathi D, Sharma S, Bandopadhyaya GP and Malhotra A: Tc-99m Tetrofosmin uptake in male breast cancer. Clin Nucl Med. 26:77–78. 2001. View Article : Google Scholar : PubMed/NCBI
37.	Kao CH, Wang SJ and Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med. 215:432–436. 1994.PubMed/NCBI
38.	Khalkhali I, Cutrone JA, Mena IG, et al: Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology. 196:421–426. 1995. View Article : Google Scholar : PubMed/NCBI
39.	Palmedo H, Biersack HJ, Lastoria S, et al: Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentric trial. Eur J Nucl Med. 25:375–385. 1998. View Article : Google Scholar : PubMed/NCBI
40.	Khalkhali I, Villanueva-Meyer J, Edell SL, et al: Diagnostic accuracy of ^99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med. 41:1973–1979. 2000.
41.	Alonso O, Massardo T, Delgado LB, et al: Is 99mTc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? J Nucl Med. 42:1614–1621. 2001.
42.	Massardo T, Alonso O, Kabasakal L, et al: Diagnostic value of 99mTc-methylene diphosphonate and 99mTc-pentavalent DMSA compared with 99mTc-sestamibi for palpable breast lesions. J Nucl Med. 43:882–888. 2002.PubMed/NCBI
43.	Taillefer R, Robidoux A, Lambert R, Turpin S and Laperriere J: Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med. 36:1758–1765. 1995.PubMed/NCBI
44.	Khalkhali I, Cutrone J, Mena I, et al: Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med. 36:1784–1789. 1995.PubMed/NCBI
45.	Palmedo H, Bender H, Grünwald F, et al: Comparison of fluorine-18 fluorodeoxiglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of brest tumours. Eur J Nucl Med. 24:1138–1145. 1997.
46.	Buscombe JR, Cwikla JB, Holloway B and Hilson AJW: Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med. 42:3–8. 2001.PubMed/NCBI
47.	Rice SJ, Khalkhali I and Diggles L: The role of radionuclide breast imaging in the evaluation of suspected breast abnormalities. Breast Dis. 10:177–187. 1998.PubMed/NCBI
48.	Cwikla JB, Buscombe JR, Kelleher SM, et al: Comparison of accuracy of scintimammography in the diagnosis of primary breast cancer in patients selected for surgical biopsy. Clin Radiol. 53:274–280. 1998. View Article : Google Scholar : PubMed/NCBI
49.	Khalkhali I and Vargas H: The role of nuclear medicine in breast cancer detection: functional breast imagery. Radiol Clin of North Am. 39:1053–1068. 2001. View Article : Google Scholar : PubMed/NCBI
50.	Koukouraki S, Koukourakis MI, Vagios E, Velidaki A, Tsiftsis D and Karkavitsas N: The role of ^99mTc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. Nucl Med Commun. 22:1243–1248. 2001.
51.	Nuclear imaging test cleared by the FDA. Women's Health Weekly, 06/09/97-06/16/97, p3,2p.
52.	Waxman A: The role of 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med. 27:40–54. 1997. View Article : Google Scholar : PubMed/NCBI
53.	Liberman M, Sampalis F, Mulder DS and Sampalis JS: Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat. 80:115–126. 2003. View Article : Google Scholar : PubMed/NCBI
54.	Hussain R and Buscombe JR: A meta-analysis of scintimammography: an evidence based approach to its clinical utility. Nucl Med Commun. 27:589–559. 2004. View Article : Google Scholar : PubMed/NCBI
55.	Barros AC, Marques JA, Souza AZ, et al: Cintilografia mamária com tecnécio-99m-sestamibi: fundamentos do método e experiência clínica inicial. Rev Ginecol Obstet. 6:119–123. 1995.
56.	Lima MCL, Cunha DC, Etchebehere ECSC, et al: Mamocintilografia com sestamibi-^99mTc no diagnóstico de lesões de mama. Rev Bras Mastol. 1:3–9. 2000.
57.	Buscombe JR, Cwikla JB, Thakrar DS and Hilson A: Uptake of Tc-99m MIBI related to tumor size and type. Anticancer Res. 17:1693–1694. 1997.PubMed/NCBI
58.	Nachar O, Rousseau J, Ouellet R, et al: Scintimammogaphy with 11β-methoxy-(17α,2OZ)-[¹²³I]Iodovinylestradiol: a complementary role to ^99mTc-metoxyisobutylisonitrile in the characterization of breast tumors. J Nucl Med. 41:1324–1331. 2000.
59.	Tavassoli FA: Pathology of the Breast. Elsevieir; New York: 1992
60.	Owen HW, Dockerty MB and Gray HK: Occult carcinoma of the breast. Surg Gynecol Obstet. 98:3021954.PubMed/NCBI
61.	Fitts WT, Steiner GC and Enterline HT: Prognosis of occult carcinoma of the breast. Am J Surg. 106:4601963. View Article : Google Scholar
62.	Haagensen CD: The diagnosis of breast carcinoma. Diseases of the Breast. Saunders WB; Philadelphia: pp. 4861971
63.	Baron PL, More MP and Kinne DW: Occult breast cancer presenting with axillary metastases: updated management. Arch Surg. 125:2101990. View Article : Google Scholar : PubMed/NCBI
64.	Scoggins CR, Vitola JV, Sandler MP, Atkinson JB and Frexes-Steed M: Occult breast carcinoma presenting as an axillary mass. Am Surg. 65:1–5. 1999.PubMed/NCBI
65.	Prats E, Aisa F, Abós MD, et al: Mammography and 99mTc-MIBI scintimammography in suspected breast cancer. J Nucl Med. 40:296–301. 1999.PubMed/NCBI
66.	Uriarte I, Carril JM, Quirce R, et al: Optimization of X-ray mammography and technetium-99m methoxyisobutylisonitrile scintimammogrpahy in the diagnosis of non-palpable breast lesions. Eur J Nucl Med. 25:491–496. 1998. View Article : Google Scholar : PubMed/NCBI
67.	Black MM, Barclay THC and Culter SJ: Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer. 29:338–343. 1972. View Article : Google Scholar : PubMed/NCBI
68.	Dupont WD and Page DL: Risk factors for breast cancer in women with proliferative breast cancer in women with proliferative breast disease. N Eng J Med. 312:146–151. 1985. View Article : Google Scholar : PubMed/NCBI
69.	Tobias P, De Luca LA, Schmitt FCL, Frederigue U Jr and Uemura G: A histological review and critical analysis of fibroadenomas. Rev Bras Mastol. 9:68–74. 1999.